基于电子密度图、有效原子序数图和碘图定量评估光谱CT在实体乳腺肿块生物学价值分型中的应用
本研究前瞻性纳入2018至2020年在大学乳腺中心因浸润性乳腺癌分期行双层光谱CT检查的患者,评估电子密度图对实体乳腺肿块生物学鉴别的价值。结果显示有效原子序数和碘含量具有较好的诊断效能,AUC为0.84至0.85,而电子密度图诊断效能较低,AUC为0.63至0.67,未显示额外诊断价值。
要点
- 有效原子序数图和碘图对乳腺良恶性肿块的鉴别诊断效能较高,AUC达0.84至0.85。
- 电子密度图诊断效能较低,AUC为0.63至0.67,未显示超越有效原子序数和碘含量的附加价值。
- 有效原子序数小于7.7、碘含量小于0.8 mg/ml为鉴别良恶性肿块的定量截断值。
核心结论
- 有效原子序数、碘含量和电子密度的定量评估确认了鉴别乳腺良恶性肿块的稳健截断值,但电子密度评估未显示超越有效原子序数和碘含量定量评估的额外诊断价值。
研究设计与样本
- 前瞻性研究,纳入2018至2020年大学乳腺中心因浸润性乳腺癌分期行双层光谱CT检查的166例检查,由4名放射科医生中的2名独立进行基于感兴趣区的半自动评估,以ROC/AUC曲线和约登指数进行统计分析。
诊断标准与关键数值
- 电子密度图在乳腺目标病灶的约登截断值分别为104.0%(阅片者1)和103.8%(阅片者2),经验截断点AUC分别为0.63和0.67。碘图约登截断值为8.0 mg/ml,有效原子序数图截断值为1.1/1.2,AUC范围为0.84至0.85(p=0.023至<0.000)。基于截断值的AUC:电子密度为0.64和0.66(阅片者1和2),有效原子序数为0.86(两名阅片者),碘含量为0.89和0.86(阅片者1和2)。有效原子序数与电子密度计算联合后AUC轻度升高(阅片者1:0.85-0.87;阅片者2:0.84-0.94)。结论确认鉴别良恶性的截断值为有效原子序数<7.7、碘含量<0.8 mg/ml。
临床应用与阅片要点
- 作者认为,有效原子序数和碘含量的定量评估可用于鉴别乳腺良恶性肿块;电子密度评估未显示额外诊断价值,需进一步研究以开发电子密度图的合适临床适应证。
局限性
- 需进一步研究以开发电子密度图的合适临床适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We aimed to asses, in a clinical setting, whether the newly available quantitative evaluation of electron density (ED) in spectral CT examinations of the breast provide information on the biological identity of solid breast masses and whether ED maps yield added value to the diagnostic information of iodine maps and Zeff maps calculated from the same CT image datasets.
METHODS: All patients at the University Breast Cancer Center who underwent a clinically indicated Dual Layer Computed Tomography (DLCT) examination for staging of invasive breast cancer from 2018 to 2020 were prospectively included. Iodine concentration maps, Zeff maps and ED maps were automatically reconstructed from the DLCT datasets. Region of interest (ROI) based evaluations in the breast target lesions and in the aorta were performed semi-automatically in identical anatomical positions using dedicated evaluation software. Case-by-case evaluations were carried independently by 2 of 4 radiologists for each examination, respectively. Statistical analysis derived from the ROIs was done by calculating ROC/AUC curves and Youden indices.
RESULTS: The evaluations comprised 166 DLCT examinations. In the ED maps the measurements in the breast target lesions yielded Youden cutpoints of 104.0% (reader 1) and 103.8% (reader 2) resulting in AUCs of 0.63 and 0.67 at the empirical cutpoints. The variables "Zeff" and "iodine content" derived from the target lesions showed superior diagnostical results, with a Youden cutpoint of 8.0 mg/ml in the iodine maps and cutpoints of 1.1/1.2 in the Zeff maps the AUCs ranging from 0.84 to 0.85 (p = 0.023 to <0.000). The computational combination of Zeff and ED measurements in the target lesions yielded a slight AUC increase (readers 1: 0.85-0.87; readers 2: 0.84-0.94). The ratios of the measured values in the target lesions normalized to the values measured in the aorta showed comparable results. The AUCs of ED derived from the cutpoints showed inferior results to those derived from the Zeff maps and iodine maps (ED: 0.64 and 0.66 for reader 1 and 2; Zeff: 0.86 for both readers; iodine content: 0.89 and 0.86 for reader 1 and 2, respectively). The computational combination of the ED results and the Zeff measurements did not lead to a clinically relevant diagnostic gain with AUCs ranging from 0.86 to 0.88.
CONCLUSIONS: Quantitative assessments of Zeff, iodine content and ED all targeting the physical and chemical aspects of iodine uptake in solid breast masses confirmed diagnostically robust cutpoints for the differentiation of benign and malignant findings (Zeff < 7.7, iodine content of <0.8 mg/ml). The evaluations of the ED did not indicate any added diagnostic value beyond the quantitative assessments of Zeff and iodine content. Further research is warranted to develop suitable clinical indications for the use of ED maps.
引用
- Klein K, Schafigh DG, Wallis MG, et al. Assignment of the biological value of solid breast masses based on quantitative evaluations of spectral CT examinations using electron density mapping, Zeffective mapping and iodine mapping. Eur J Radiol. 2023. PMID: 38219351. doi:10.1016/j.ejrad.2023.111280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。